Assess whether scientific advice should be sought before the next trial

SITUATION An RWE group proposing a post-marketing study instead of a new RCT cannot treat an AdCom briefing document that overstates subgroup findings as incidental context on phase-3 protocol with endpoint-sensitivity issues. Clinical-development physician must close scientific advice should be from that extract under Pharma & Life Sciences / CMC and Development Pathways.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one an AdCom briefing document that overstates subgroup findings named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained an AdCom briefing document that overstates subgroup findings before phase-3 protocol with endpoint-sensitivity issues arrived; no new CMC and Development Pathways path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after an AdCom briefing document that overstates subgroup findings is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after an AdCom briefing document that overstates subgroup findings. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against an AdCom briefing document that overstates subgroup findings and write the one fact that would move scientific advice should be for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.